Press Releases
iCAD’s “ProFound Insights, ProFound Impact” Webinar Series to Highlight ProFound AI Risk
Leading experts, including distinguished researchers from the Karolinska Institutet and clinicians using it in daily practice, to discuss significant impact and value of technology NASHUA, N.H. – June 7, 2022 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced…
iCAD to Present at the JMP Securities Life Sciences Conference on June 15-16, 2022
NASHUA, N.H., June 6, 2022 — iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will participate in the JMP Securities Life Sciences Conference, taking place June 15-16, 2022 in New York City. Stacey Stevens, President and CEO of…
iCAD Announces CFO Transition
Stephen P. Sarno appointed as interim Chief Financial Officer to the Company, effective immediately NASHUA, N.H., May 25, 2022 — iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Board of Directors has approved the appointment of Stephen P. Sarno…
New Real-World Evidence Shows ProFound AI Improves Cancer Detection and Accuracy with Digital Breast Tomosynthesis, or 3D Mammography
Research presented at the 2022 SBI/ACR Breast Imaging Symposium confirms ProFound AI significantly enhances radiologists’ screening performance NASHUA, N.H., May 18, 2022 — iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that new research supporting ProFound AI® for Digital Breast…
New Research Finds iCAD’s ProFound AI Risk for Digital Breast Tomosynthesis is 2.4x More Accurate than Traditional Lifetime Risk Models
Using U.S. guidelines, ProFound AI Risk found 14% of women studied who had a negative screen had almost 20 times higher risk of developing breast cancer in the next year than the general risk population iCAD recently announced that promising clinical research supporting ProFound AI® Risk for Digital…
iCAD to Present at the Spring Into Action – Best Ideas Virtual Investor Conference on May 17th, 2022
NASHUA, N.H., May 12, 2022 — iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will present at the Spring Into Action – Best Ideas Virtual Investor Conference, which is being held virtually on May 16th – 20th, 2022….
iCAD Reports Financial Results for First Quarter Ended March 31, 2022
Company to host conference call and webcast today at 4:30 PM ET NASHUA, N.H. – May 11, 2022 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the three months ended March 31, 2022. Highlights:…
iCAD’s “ProFound Insights, ProFound Impact” Webinar Series to Feature Clinical and IT Experts from Wake Radiology
Leading healthcare provider with 14 imaging centers in North Carolina identified ProFound AI as the premier solution in a competitive trial based on unique workflow benefits and multivendor flexibility NASHUA, N.H. – April 28, 2022 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection…
iCAD to Report First Quarter 2022 Financial Results on Wednesday, May 11
NASHUA, N.H. – April 27, 2022 – iCAD®, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the first quarter ended March 31, 2022, after the market close, and host a conference call at 4:30 PM…
iCAD Announces Significant Commercial Momentum for ProFound AI® Among Customers Equipped with the Leading Provider of 3D Mammography Systems
Customers report continued workflow advantages and clinical superiority with iCAD’s suite of AI-powered breast health solutions, compared to other available breast AI solutions NASHUA, N.H. – April 26, 2022 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, announced significant…